全文获取类型
收费全文 | 41343篇 |
免费 | 4658篇 |
国内免费 | 344篇 |
专业分类
耳鼻咽喉 | 940篇 |
儿科学 | 1035篇 |
妇产科学 | 880篇 |
基础医学 | 4039篇 |
口腔科学 | 1237篇 |
临床医学 | 4864篇 |
内科学 | 8553篇 |
皮肤病学 | 916篇 |
神经病学 | 4127篇 |
特种医学 | 1746篇 |
外科学 | 6719篇 |
综合类 | 359篇 |
现状与发展 | 2篇 |
一般理论 | 31篇 |
预防医学 | 3794篇 |
眼科学 | 1111篇 |
药学 | 2618篇 |
中国医学 | 57篇 |
肿瘤学 | 3317篇 |
出版年
2023年 | 609篇 |
2022年 | 287篇 |
2021年 | 690篇 |
2020年 | 994篇 |
2019年 | 663篇 |
2018年 | 1167篇 |
2017年 | 1038篇 |
2016年 | 1212篇 |
2015年 | 1221篇 |
2014年 | 1775篇 |
2013年 | 2422篇 |
2012年 | 2325篇 |
2011年 | 2410篇 |
2010年 | 1816篇 |
2009年 | 2038篇 |
2008年 | 2381篇 |
2007年 | 2493篇 |
2006年 | 2583篇 |
2005年 | 2372篇 |
2004年 | 2305篇 |
2003年 | 2174篇 |
2002年 | 2125篇 |
2001年 | 483篇 |
2000年 | 304篇 |
1999年 | 491篇 |
1998年 | 698篇 |
1997年 | 641篇 |
1996年 | 660篇 |
1995年 | 582篇 |
1994年 | 459篇 |
1993年 | 394篇 |
1992年 | 284篇 |
1991年 | 315篇 |
1990年 | 215篇 |
1989年 | 265篇 |
1988年 | 220篇 |
1987年 | 209篇 |
1986年 | 196篇 |
1985年 | 245篇 |
1984年 | 300篇 |
1983年 | 228篇 |
1982年 | 314篇 |
1981年 | 291篇 |
1980年 | 285篇 |
1979年 | 142篇 |
1978年 | 151篇 |
1977年 | 152篇 |
1976年 | 112篇 |
1975年 | 112篇 |
1974年 | 84篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
4.
5.
6.
7.
8.
9.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
10.